Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2021 | IsoPlexis | Series D | 85M |
| 4/2021 | Renovia | Series C | 0 |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 3/2021 | Absci | Venture Round | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 7/2020 | Genome Medical | Series B | 0 |
| 5/2017 | Synlogic | Series C | 42M |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 8/2020 | ReViral | Series C | 0 |
| 4/2022 | Surf Bio | Seed | 16M |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 11/2020 | Adagio Medical | Series E | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 9/2014 | Affimed | Debt Financing | 14M |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 9/2020 | Willow | Series C | 0 |
| 4/2021 | Forge Biologics | Series B | 120M |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 10/2021 | Honor | Debt Financing | 300M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 5/2017 | Xontogeny | Series A | 15M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 5/2019 | ArcherDX | Series B | 60M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 12/2019 | ArcherDX | Series C | 0 |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 9/2018 | Vapotherm | Series D | 0 |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 1/2021 | Earli | Series A | 40M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 10/2021 | Twin Health | Series C | 155M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 11/2017 | Counsyl | Equity | 80M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 6/2020 | DNAnexus | Series G | 0 |
| 5/2017 | Outset Medical | Series C | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 3/2019 | Saama | Venture Round | 40M |
| 5/2021 | Cue | Venture Round | 235M |
| 6/2016 | VitalConnect | Series B | 18M |
| 10/2020 | LianBio | Series A | 0 |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 4/2019 | Kindbody | Series A | 15M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 8/2020 | Freenome | Series C | 270M |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 8/2018 | ReViral | Series B | 0 |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 11/2021 | Sermonix | Series A | 40M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 3/2022 | VivoSense | Series A | 0 |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 1/2021 | Affinivax | Series C | 226M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 7/2020 | Kindbody | Series B | 0 |
| 12/2020 | Neuron23 | Series B | 80M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 2/2022 | Synthego | Series E | 0 |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 3/2022 | DNAnexus | Series H | 200M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 7/2019 | Freenome | Series B | 160M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 4/2014 | Otonomy | Series D | 49M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 3/2022 | Neuron23 | Series C | 0 |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 8/2020 | Metabolon | Venture Round | 72M |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
